New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment Journal Article


Authors: Ladanyi, M.; Zauderer, M. G.; Krug, L. M.; Ito, T.; McMillan, R.; Bott, M.; Giancotti, F.
Article Title: New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment
Abstract: Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM,ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM. ©2012 AACR.
Journal Title: Clinical Cancer Research
Volume: 18
Issue: 17
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2012-09-01
Start Page: 4485
End Page: 4490
Language: English
DOI: 10.1158/1078-0432.ccr-11-2375
PROVIDER: scopus
PMCID: PMC3432735
PUBMED: 22825583
DOI/URL:
Notes: --- - "Export Date: 1 October 2012" - "CODEN: CCREF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Lee M Krug
    211 Krug
  2. Marc Ladanyi
    861 Ladanyi
  3. Matthew Bott
    33 Bott
  4. Tatsuo Ito
    8 Ito